Side-by-side · Research reference

FOXO4-DRIvsHexarelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BPhase 1HUMAN-REVIEWED19/45 cited

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

Hexarelin

Hexapeptide GHRP · Cardio-tropic

100–200 mcgPer doseSmith 1996

Phase 1Evidence levelGhigo 1997

~70 minHalf-lifeSemenistaya 2010

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

FOXO4-DRI

Hexarelin

Primary target

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996 Ghigo 1997

Pathway

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997

Downstream effect

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997

Feedback intact?

—

Yes initially; tachyphylaxis with chronic useGhigo 1997

Origin

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996

Antibody development

—

02Dosage Protocols

Parameter

FOXO4-DRI

Hexarelin

Animal dose (mouse)

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

—

Frequency (animal)

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

—

Human equivalent (theoretical)

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

—

Evidence basis

Animal / mechanistic

Phase 1 / Phase 2 trialsSmith 1996 Ghigo 1997

Route

SQ (animal)

No human route established.

—

Duration

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)

Clinical status

No human trials completed

—

Standard dose

—

100–200 mcg per injectionSmith 1996

Frequency

—

1–2× per day max (tachyphylaxis with chronic 3× daily)

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

Half-life

—

~70 minSemenistaya 2010

04Side Effects & Safety

Parameter

FOXO4-DRI

Hexarelin

Pulmonary hypertension risk

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

—

Context-dependent toxicity

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

—

Off-target apoptosis

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

—

Immune perturbation

Senescent cells contribute to immune surveillance; clearance effects unknown

—

Human safety unknown

No clinical trials — toxicity profile in humans not established

—

Cortisol elevation

—

Modest at high dosesGhigo 1997

Prolactin elevation

—

Modest at high dosesGhigo 1997

Hunger

—

Strong appetite increase via ghrelin agonism

Tachyphylaxis

—

Receptor desensitisation with chronic dosingGhigo 1997

Cardiac effects

—

Direct cardio-tropic; potential benefit in MI but unstudied in humansGhigo 1997

IGF-1 elevation

—

Strong; monitor with chronic high-dose use

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Absolute Contraindications

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

Hexarelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

Hexarelin

·Untreated diabetes
·Severe hyperprolactinemia

05Administration Protocol

Parameter

FOXO4-DRI

Hexarelin

1. Pre-clinical route

Subcutaneous injection used in rodent models. No human administration protocol exists.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Reconstitution (animal)

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

SQ — abdomen or thigh. Rotate sites.

3. Dosing schedule

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.

4. Clinical development status

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Safety monitoring (proposed)

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

FOXO4-DRI

— no documented stacks

Hexarelin

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

Hexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.

Hexarelin: 100 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Maximum GH pulse amplitude (with side-effect signal)

Smith 1996 Teichman 2006